Oncolytics Biotech Inc.
ONCY
$0.80
-$0.01-1.24%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 95.07% | 77.52% | 53.73% | 30.45% | -7.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.49% | 32.53% | 9.30% | 3.04% | -11.03% |
| Operating Income | -58.49% | -32.53% | -9.30% | -3.04% | 11.03% |
| Income Before Tax | -63.23% | -45.36% | -23.71% | -32.99% | -12.66% |
| Income Tax Expenses | 31.42% | -20.24% | -20.24% | -192.35% | -14.88% |
| Earnings from Continuing Operations | -63.11% | -45.08% | -23.53% | -31.77% | -12.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -63.11% | -45.08% | -23.53% | -31.77% | -12.52% |
| EBIT | -58.49% | -32.53% | -9.30% | -3.04% | 11.03% |
| EBITDA | -58.79% | -32.74% | -9.41% | -3.07% | 11.12% |
| EPS Basic | -21.64% | -9.84% | 3.10% | -11.46% | -1.10% |
| Normalized Basic EPS | -21.73% | -9.98% | 3.01% | -12.31% | -1.19% |
| EPS Diluted | -21.64% | -9.84% | 3.10% | -11.46% | -1.10% |
| Normalized Diluted EPS | -21.73% | -9.98% | 3.01% | -12.31% | -1.19% |
| Average Basic Shares Outstanding | 33.14% | 30.32% | 25.28% | 17.33% | 11.96% |
| Average Diluted Shares Outstanding | 33.14% | 30.32% | 25.28% | 17.33% | 11.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |